Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05329350Recruiting
Device follow-up for a small hole in the heart
This follow-up study monitors how well and how safely the Occlutech mVSD device works to close certain muscular heart “holes” (ventricular septal defects). You may join if you already had the device placed and can return for scheduled checkups to help doctors learn long-term outcomes.
DublinAges 3 months–80 years - NCT07082725RecruitingPhase 3
Study of oral nizubaglustat for Niemann-Pick type C
This study tests an oral medication called nizubaglustat for people with Niemann-Pick type C disease who cannot take or are not satisfied with the current treatment miglustat. It aims to see if the drug can help with symptoms like coordination and movement problems.
Oakland, CaliforniaAges 4 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT07039916RecruitingPhase 3
Study of IMVT-1402 for mild to severe generalized myasthenia gravis
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Huntsville, AlabamaAges 18–80 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Fountain Valley, CaliforniaAges 18 years+ - NCT07322003RecruitingPhase 3
Pridopidine for ALS: Phase 3 trial testing safety and effectiveness
This trial is testing if an oral medication called pridopidine can slow the progression of ALS. It is for people recently diagnosed with ALS who have mild to moderate breathing function and meet specific risk scores.
Phoenix, ArizonaAges 18–80 - NCT05334368RecruitingPhase 3
Depemokimab for hypereosinophilic syndrome with frequent flares
This trial studies depemokimab, a medicine meant to reduce flares in people with hypereosinophilic syndrome (HES). It also checks how safe the treatment is and how well it works over time.
San Diego, CaliforniaAges 18 years+ - NCT07565285RecruitingPhase 2
Combination Treatment for Operable Stage III Skin Melanoma
This study tests whether combining a new drug called PRTX007-003 with pembrolizumab (an immunotherapy) can help prevent melanoma from returning after surgery. You would receive both treatments after your tumor is surgically removed.
Waratah, New South WalesAges 18 years+ - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Birmingham, AlabamaAges 18–65 - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Phoenix, ArizonaAges 55–90 - NCT07256392Enrolling by invitationPhase 3
Long-term safety of barzolvolimab for chronic hives
This study is a long-term extension of the barzolvolimab trial for people with chronic spontaneous urticaria (CSU). It tests the continued safety and effectiveness of barzolvolimab over a longer period for those who have already completed the initial phase 3 study.
Birmingham, AlabamaAges 18 years+ - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Lancaster, CaliforniaAges 18–75 - NCT07084012RecruitingPhase 2
Stem cell treatment for recent stroke
This trial tests whether a single infusion of umbilical cord stem cells can help people recover from a recent ischemic stroke (stroke caused by a clot). It is for patients who have had their stroke within the last 72 hours and have moderate to severe symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT03945305Recruiting
Remote ischemic conditioning for high blood pressure
This trial tests if a simple, non-invasive treatment called remote ischemic conditioning (briefly restricting blood flow to an arm) can safely lower blood pressure in people with essential hypertension. It is for adults aged 30-75 whose blood pressure is consistently high despite standard care.
Changchun, JilinAges 30–75 - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT07190196RecruitingPhase 3
Study of Rilzabrutinib for IgG4-related disease
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
Fontana, CaliforniaAges 18 years+ - NCT06742723RecruitingPhase 3
Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Fairhope, AlabamaAges 18 years+ - NCT04752774RecruitingPhase 1/Phase 2
Botox-like injection study for arm spasticity after stroke
This trial tests whether IPN10200, a Botox-like treatment, is safe and helps reduce stiff, tight upper-arm muscles caused by spasticity after stroke or brain injury. You may be able to join if you meet specific timing, prior-treatment, and muscle-stiffness measurements.
Downey, CaliforniaAges 18–70 - NCT07546032Recruiting
Nail Psoriasis Treatment Device Study
This study tests a medical device called PROXERA PSOMED 30 to see if it safely and effectively treats nail psoriasis (psoriasis affecting fingernails or toenails). If you have nail psoriasis, this trial may help determine whether this device works better than current treatments.
Chieti, ItaliaAges 18–65 - NCT07177339RecruitingPhase 3
Testing depemokimab for COPD with type 2 inflammation
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Newport Beach, CaliforniaAges 40–75 - NCT04713787RecruitingPhase 2
Test higher doses of oxfendazole against single-dose albendazole
This trial studies which dose of oxfendazole works best and is safest for treating a specific intestinal worm infection in adults. It compares different oxfendazole doses to one standard dose of albendazole, and uses stool and blood testing over about 4–6 weeks.
Santa Clara, MaynasAges 18–65 - NCT07497880RecruitingPhase 2
Study of a new pill for weight loss in adults with obesity
This trial tests a daily pill called KAI-7535 to see if it helps people with obesity or overweight lose weight safely. It is for adults who have a body mass index (BMI) of 27 or higher and at least one weight-related health problem, such as high blood pressure or type 2 diabetes.
Chandler, ArizonaAges 18–75 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.